Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12539090.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD20
- Antineoplastic Agents
- Meningoencephalitis